News & Updates
Filter by Specialty:
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
Evaluation and treatment rates of patients with chronic hepatitis B (CHB) remain poor worldwide and differ by sex and race or ethnicity, reports a real-world study.
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
19 Jul 2024
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
10 Jul 2024
SABR yields better survival, tumour control in oligometastatic HCC
Treatment with stereotactic ablative radiotherapy (SABR) results in excellent local tumour control and improves survival among patients with oligometastatic hepatocellular carcinoma (HCC), with no serious adverse effects, reports a study.
SABR yields better survival, tumour control in oligometastatic HCC
05 Jul 2024
Liver stiffness predicts decompensation, mortality in ALD patients
Clinicians may use liver stiffness measurement (LSM) by transient elastography (TE) to accurately predict decompensation and all-cause mortality in patients with compensated alcohol-related liver disease (ALD), suggests a study.
Liver stiffness predicts decompensation, mortality in ALD patients
04 Jul 2024
Exercise, Mediterranean diet remain key against MASLD
A 12-week lifestyle intervention comprising a moderate-intensity physical activity (PA) programme and a hypocaloric Mediterranean diet (MD) promoted fat removal and liver fibrosis improvement in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), findings from the EHmet-DIA study suggest.